Keeping Emotional Responses at the Center of the Design

Whether you’re an integrator, a designer or simply a label-defying creative, the experience is everything. Host Bryan Meszaros explores the story behind the exhibit to understand how a carefully crafted experience traps into the human experience to connect people to place.

 

Design can transport the mind and invoke emotions, and that’s the point of it, especially experiential projects. Digging into the experiences of design once again, Experience by Design host Bryan Meszaros welcomed Jonathan Alger to the show to discuss these topics and a recent project. Alger is the Managing Partner and Co-Founder of C&G Partners. He has an impressive career working with some of the most prominent brands in the world.

Meszaros and Alger spoke about a recent installation for Memorial Sloan Kettering Cancer Center.

“They were looking for a positive distraction art form, an environmental feature that creates positive feelings and distracts from negativity and worrisome thoughts,” Alger said.

Alger and team worked on two different designs. One was for the main lobby and the other on the sixth floor. “The first floor is a naturalistic, ever-lasting animation of bonsai, butterflies, koi fish, and blooming plants,” Alger described. What makes this so unique is the use of fiber optics and wood. It creates a meditative and calming environment, as nature tends to do. See its beauty here.

The sixth floor includes a virtual koi pond in collaboration with Potion. The environment evolves with color and light, changing season for an immersive experience.

In discussing these emotive works, Meszaros and Alger explored what it means to have an immersive experience with art and the path to appealing to emotions. “I hear from clients they want to appeal to emotions, and I ask, ‘Which one?’”

Alger referenced the movie Inside Out as a good way to broach the topic since it gives life to the five critical human emotions. The experiences that come from design can be impacting and completely change the experiencer, which was certainly the goal for those facing a health crisis.

Join host Bryan Meszaros on Experience by Design every other Wednesday as he explores the latest trends and solutions helping craft the world’s most intriguing experiences.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More